Global Lennox-Gastaut Syndrome Treatment Market 2019-2023
SKU ID : TNV-14056324 | Publishing Date : 21-Mar-2019 | No. of pages : 116
Detailed TOC of Global Lennox-Gastaut Syndrome Treatment Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Non-surgical treatment - Market size and forecast 2018-2023
• Surgical treatment - Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eisai Co., Ltd.
• GlaxoSmithKline plc.
• H. Lundbeck A/S
• Johnson & Johnson Services, Inc.
• Supernus Pharmaceuticals, Inc
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global LGS treatment market pipeline: Overview
Exhibit 18: Phase III pipeline molecules: Overview
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Non-surgical treatment - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Non-surgical treatment - Year-over-year growth 2019-2023 (%)
Exhibit 23: Surgical treatment - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Surgical treatment - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: LGS drugs that received orphan drug designation from US FDA: Overview
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Eisai Co., Ltd. - Vendor overview
Exhibit 51: Eisai Co., Ltd. - Business segments
Exhibit 52: Eisai Co., Ltd. - Organizational developments
Exhibit 53: Eisai Co., Ltd. - Geographic focus
Exhibit 54: Eisai Co., Ltd. - Segment focus
Exhibit 55: Eisai Co., Ltd. - Key offerings
Exhibit 56: Eisai Co., Ltd. - Key customers
Exhibit 57: GlaxoSmithKline plc. - Vendor overview
Exhibit 58: GlaxoSmithKline plc. - Business segments
Exhibit 59: GlaxoSmithKline plc. - Organizational developments
Exhibit 60: GlaxoSmithKline plc. - Geographic focus
Exhibit 61: GlaxoSmithKline plc. - Segment focus
Exhibit 62: GlaxoSmithKline plc. - Key offerings
Exhibit 63: GlaxoSmithKline plc. - Key customers
Exhibit 64: H. Lundbeck A/S - Vendor overview
Exhibit 65: H. Lundbeck A/S - Business segments
Exhibit 66: H. Lundbeck A/S - Organizational developments
Exhibit 67: H. Lundbeck A/S - Geographic focus
Exhibit 68: H. Lundbeck A/S - Key offerings
Exhibit 69: H. Lundbeck A/S - Key customers
Exhibit 70: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 71: Johnson & Johnson Services, Inc. - Business segments
Exhibit 72: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 73: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 74: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 75: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 76: Johnson & Johnson Services, Inc. - Key customers
Exhibit 77: Supernus Pharmaceuticals, Inc - Vendor overview
Exhibit 78: Supernus Pharmaceuticals, Inc - Business segments
Exhibit 79: Supernus Pharmaceuticals, Inc - Organizational developments
Exhibit 80: Supernus Pharmaceuticals, Inc - Key offerings
Exhibit 81: Supernus Pharmaceuticals, Inc - Key customers
Exhibit 82: Validation techniques employed for market sizing
Keyplayers in Global Lennox-Gastaut Syndrome Treatment Market 2019-2023
Eisai Co., Ltd.GlaxoSmithKline plc.
H. Lundbeck A/S
Johnson & Johnson Services, Inc.
Supernus Pharmaceuticals, Inc